A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

NCT06166056 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Bronchiectasis

Interventions

DRUG: CHF6333
DRUG: CHF6333 Placebo

Sponsor

Chiesi Farmaceutici S.p.A.